CNC
Strong BuySecond WindFLAGCentene Corporation · Healthcare · United States · $32.0B · Avg Vol: $271M/d
Second Wind: Cheap and rising again, but the business does not yet earn the optimism.
Centene has the weakest quality reading in this batch at Q42 with M86 doing nearly all the work, and insiders have sold. A composite this dependent on momentum, with quality that far below the midpoint and insider selling on record, is adverse evidence rather than thin information.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT CENTENE CORPORATION
Read
Centene Corporation is a prominent diversified healthcare enterprise specializing in government-sponsored healthcare programs, including Medicaid, Medicare, and the Health Insurance Marketplace. Its competitive moat derives from its vast scale, deep expertise in navigating complex regulatory environments, and efficient management of care for underserved populations. Centene is a market leader in the U.S. managed care sector, particularly within the Medicaid segment.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 144.5B | 154.0B | 163.1B | 194.8B | 10.5% | 180.3B | 195.9B | 193.5B | -0.3% |
| EPS | 2.09 | 4.97 | 6.33 | -13.53 | 74.0% | -10.36 | — | — | — |
| Shares | 550.8M | 534.5M | 495.9M | 491.8M | -10.7% | 494.0M | — | — | — |
| Debt | 21.3B | 18.9B | 19.4B | 18.2B | -5.2% | 16.1B | — | — | — |
| Equity | 24.1B | 25.8B | 26.4B | 20.0B | -6.0% | — | — | — | — |
| Op CF | 6.3B | 8.1B | 154.0M | 5.1B | -6.7% | 9.7B | — | — | — |
| Inv CF | -2.9B | -1.2B | -1.1B | 472.0M | — | — | — | — | — |
| Fin CF | -4.2B | -1.7B | -2.4B | -1.6B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CNC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CNC | Centene Corporation(you) | $32.0B | 93 | Strong Buy |
| HUM | Humana Inc. | $46.3B | 89 | Strong Buy |
| CI | The Cigna Group | $73.7B | 92 | Strong Buy |
| ELV | Elevance Health, Inc. | $85.5B | 90 | Strong Buy |
| CVS | CVS Health Corporation | $119.0B | 93 | Strong Buy |
| OSCR | Oscar Health, Inc. | $9.4B | 98 | Strong Buy |
| MOH | Molina Healthcare, Inc. | $10.4B | 71 | Buy |
| UNH | UnitedHealth Group Incorporated | $352.7B | 90 | Strong Buy |
| PGNY | Progyny, Inc. | $2.0B | 98 | Strong Buy |
| CLOV | Clover Health Investments, Corp. | $2.2B | 79 | Buy |
Peer medians: ROE -31.0% · P/E 25.1x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.